SABS — SAB BIOTHERAPEUTICS INC

Ownership history in Commodore Capital LP  ·  4 quarters on record

This page tracks every 13F SEC filing in which Commodore Capital LP reported a position in SAB BIOTHERAPEUTICS INC (SABS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.1% (2025 Q4)
Avg. % of fund
0.67%
First filed
2023 Q4
Last filed
2025 Q4
Quarters held
4
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 4,401,500 — 0% 1.10% $16.5M $3.74
2025 Q3 ADDED 4,401,500 +4,218,326 +2302.9% 0.43% $8.8M $2.01
2024 Q1 REDUCED 183,174 -1,648,572 -90.0% 0.06% $832K $4.54
2023 Q4 INITIATED 1,831,746 — — 1.09% $12.6M —
% of Fund (quarterly)    SABS price (monthly, adj. close)

Other funds also holding SABS

As of 2025 Q4 — sorted by position size

Vivo Capital, LLC 3Y 7Y 2.76% Propel Bio Management, LLC 2.08% CAXTON CORP 3Y 7Y 0.92% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 0.17% Sessa Capital IM, L.P. 3Y 7Y 0.15% STEMPOINT CAPITAL LP 0.09% AWM Investment Company, Inc. 3Y 7Y 0.07% PERCEPTIVE ADVISORS LLC 3Y 7Y 0.05% FIFTH LANE CAPITAL, LP 3Y 0.04% Woodline Partners LP 3Y 0.04%
← Back to Commodore Capital LP Holdings